Nitric oxide, oxygen, and prostacyclin in children with pulmonary hypertension
Open Access
- 1 February 1998
- Vol. 79 (2) , 169-174
- https://doi.org/10.1136/hrt.79.2.169
Abstract
Objective—To test the vasodilatory response of the pulmonary vascular bed in children with pulmonary hypertension. Design—Prospective dose response study in which the effects of inhaled nitric oxide (NO) are compared with those of oxygen and intravenous prostacyclin. Patients and interventions—The vasodilator test was performed in 20 patients in whom mean pulmonary artery pressure (PAPm) was ⩾ 40 mm Hg and/or pulmonary vascular resistance index was ⩾ 4 Um2. Haemodynamic effects of inhaled NO (20, 40, and 80 ppm) at a fractional inspired oxygen (FiO2) value of 0.3, pure oxygen, oxygen at FiO2 0.9-1.0 combined with NO as above or with intravenous prostacyclin at 10 and 20 ng/kg/min were measured. Result—NO decreased PAPm with a dose response from 20 to 40 ppm (mean change at 40 ppm −5.50, 95% confidence interval (CI) −7.98 to −3.02 mm Hg). Maximal decrease in the ratio of pulmonary to systemic vascular resistance was achieved with a combination of NO 80 ppm and oxygen (−0.18, 95% CI −0.26 to −0.10). Increase in the pulmonary flow index was greatest with pure oxygen in those with an intracardiac shunt (8.52, 95% CI −0.15 to 17.20 l/min/m2). Neither NO nor oxygen altered systemic arterial pressure but intravenous prostacyclin lowered systemic arterial pressure and resistance. Conclusions—NO selectively reduces pulmonary vascular resistance and pressure maximally at 40 ppm. Oxygen reduces pulmonary vascular resistance and NO potentiates this reduction without affecting the systemic circulation. Prostacyclin vasodilates the pulmonary and the systemic circulations. Keywords: pulmonary hypertension; nitric oxide; prostacyclin; congenital heart disease; childrenKeywords
This publication has 27 references indexed in Scilit:
- Inhaled nitric oxide to test the vasodilator capacity of the pulmonary vascular bed in children with long-standing pulmonary hypertension and congenital heart diseaseThe American Journal of Cardiology, 1996
- Nitric oxide is superior to prostacyclin for pulmonary hypertension after cardiac operationsThe Annals of Thoracic Surgery, 1995
- Continuous low dose inhaled nitric oxide for treatment of severe pulmonary hypertension after cardiac surgery in paediatric patients.Heart, 1995
- Therapeutic use of inhaled nitric oxideCurrent Opinion in Pediatrics, 1994
- Guidelines for the safe administration of inhaled nitric oxide.Archives of Disease in Childhood: Fetal & Neonatal, 1994
- Relief of severe pulmonary hypertension after closure of a large ventricular septal defect using low dose inhaled nitric oxideIntensive Care Medicine, 1993
- Inhaled nitric oxide for postoperative pulmonary hypertension in patients with congenital heart defectsThe Lancet, 1992
- Inhaled Nitric Oxide after Mitral Valve Replacement in Patients with Chronic Pulmonary Artery HypertensionAnesthesiology, 1992
- Safety guidelines for use of nitric oxideThe Lancet, 1992
- Inhaled Nitric Oxide A Selective Pulmonary Vasodilator of Heparin-Protamine Vasoconstriction in SheepAnesthesiology, 1991